(0.17%) 5 163.75 points
(0.14%) 38 887 points
(0.13%) 18 025 points
(1.11%) $78.98
(-0.05%) $2.14
(0.78%) $2 326.50
(2.42%) $27.34
(0.92%) $974.20
(-0.01%) $0.929
(-0.30%) $10.84
(-0.28%) $0.795
(-0.09%) $91.37
-92.64% $ 0.00850
Live Chart Being Loaded With Signals
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties...
Stats | |
---|---|
आज की मात्रा | 1.94M |
औसत मात्रा | 876 957 |
बाजार मूल्य | 582 482 |
EPS | $0 ( 2023-11-08 ) |
Last Dividend | $0.110 ( 2023-04-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.142 |
ATR14 | $0.00500 (58.82%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-02-15 | Hogan H Michael Iii | Buy | 0 | |
2022-12-30 | Weber David Allen | Sell | 91 636 | Common Stock |
2022-12-28 | Cayer Paul E | Sell | 40 054 | Common Stock |
2022-11-28 | Capps Vickie L | Sell | 42 242 | Common Stock |
2022-06-21 | Schroeder Theodore R | Buy | 27 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
-37.51 |
Last 98 transactions |
Buy: 7 968 332 | Sell: 3 029 863 |
मात्रा सहसंबंध
Otonomy Inc सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Otonomy Inc सहसंबंध - मुद्रा/वस्त्र
Otonomy Inc वित्तीय
Annual | 2021 |
राजस्व: | $125 000 |
सकल लाभ: | $-245 000 (-196.00 %) |
EPS: | $-0.810 |
FY | 2021 |
राजस्व: | $125 000 |
सकल लाभ: | $-245 000 (-196.00 %) |
EPS: | $-0.810 |
FY | 2020 |
राजस्व: | $273 000 |
सकल लाभ: | $-915 000 (-335.16 %) |
EPS: | $-1.100 |
FY | 2019 |
राजस्व: | $600 000 |
सकल लाभ: | $-312 000 (-52.00 %) |
EPS: | $-1.450 |
Financial Reports:
No articles found.
Otonomy Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.110 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.110 | 2023-04-11 |
Last Dividend | $0.110 | 2023-04-11 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.110 | -- |
Avg. Dividend % Per Year | 39.17% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.110 | 117.50% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -402.60 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.526 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0949 | 1.500 | -0.0565 | -0.0848 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 6.52 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 6.28 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.28 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.166 | -1.500 | 7.24 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -31.04 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.669 | 2.00 | -0.223 | -0.446 | [0 - 30] |
freeCashFlowPerShareTTM | -0.673 | 2.00 | -0.337 | -0.673 | [0 - 20] |
debtEquityRatioTTM | -0.0285 | -1.500 | -0.114 | 0.171 | [0 - 2.5] |
grossProfitMarginTTM | -1.960 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -397.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.68 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00131 | 0.800 | -3.32 | -2.66 | [0.5 - 2] |
Total Score | -3.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.0107 | 1.000 | -0.102 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0949 | 2.50 | -0.0363 | -0.0848 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.673 | 2.00 | -0.224 | -0.673 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.669 | 2.00 | -0.223 | -0.446 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -339.34 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.609 |
Otonomy Inc
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं